Role of brentuximab vedotin in the treatment of relapsed or refractory hodgkin lymphoma

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 79-85

  Siddiqi, Tanya ^a   Thomas, Sandra H ^a   Chen, Robert ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antibody drug conjugate; Brentuximab vedotin; CD 30; Hodgkin lymphoma

Indexed keywords

BRENTUXIMAB VEDOTIN;

ALOPECIA; ANEMIA; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; REVIEW; SCHOOL CHILD; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

EID: 84894529179     PISSN: None     EISSN: 11787066     Source Type: Book Series    
DOI: 10.2147/PGPM.S57700     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004;22(14):2835-2841.
4. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
5. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J. 2009;15(2):161-163.
6. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(10): 1065-1072.
7. Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. ASH Education Program Book. 2008;2008(1):326-333.
8. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;32(7): 673-679.
9. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: World Health Organization Press; 2008;2.
10. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1-14.
11. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem. 1997;272(4):2042-2045.
12. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848-1854.
13. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-179.
14. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29.
15. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1): 248-255.
16. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
17. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
18. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-568.
19. Evens AM, Fenske TS, Hamlin P, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2013;122(21):4380.
20. Wagner-Johnston ND, Bartlett NL, Cashen A, Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012;53(11):2283-2286.
21. City of Hope Medical Center. Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2011 [updated December 19, 2013]. Available from http://clinicaltrials.gov/show/NCT01393717. NLM identifier: NCT01393717. Accessed January 31, 2014.
22. Memorial Sloan-Kettering Cancer Center. Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated October 16, 2013]. Available from http://clinicaltrials.gov/ct2/show/NCT01508312?term=NCT01508312&rank=1. NLM identifier: NCT01508312. Accessed January 31, 2014.
23. Seattle Genetics, Inc. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated January 13, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01100502?term=NCT01100502&rank=1. NLM identifier: NCT01100502. Accessed January 31, 2014.
24. Millennium Pharmaceuticals, Inc. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2014 [updated January 6, 2014]. Available from http://clinicaltrials.gov/ct2/show/NCT01712490?term=NCT01712490&rank=1. NLM identifier: NCT01712490. Accessed January 31, 2014.
25. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348-1356.
26. Seattle Genetics, Inc. A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated December 20, 2013]. Available from http://clinicaltrials.gov/show/NCT01716806. NLM identifier: NCT01716806. Accessed January 31, 2014.
27. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379-6381.
28. Chen R, Forman SJ, Palmer J, et al. Two-year follow-up of patients with relapsed/refractory Hodgkin treated with brentuximab vedotin prior to reduced intensity allogeneic hematopoietic cell transplantation. Presented at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013.
29. Chen RW, Palmer J, Siddiqi T, et al. Brentuximab vedotin as first line salvage therapy in relapsed/refractory HL. ASH Annual Meeting Abstracts. 2012;120(21):3699.
30. Moskowitz AJ, Schoder H, Gerecitano J, et al. PET-adapted sequential therapy with brentuximab vedotin and augmented-ICE induces FDG-PET normalization in 92% of patients with relapsed and refractory Hodgkin lymphoma. Presented at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-22, 2013.
31. Goyal SD, Bartlett NL. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma? Curr Hematol Malig Rep. 2012;7(3):179-185.
32. Bartlett N, Brice P, Chen RW, et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study. ASCO Meeting Abstracts. 2012;30(Suppl 15):8027.
33. Forero-Torres A, Berryman RB, Advani RH, et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). ASH Annual Meeting Abstracts. 2011; 118(21):3711.